Dr. Jun Cao: Enhancing Quality of Life in HR⁺ Breast Cancer—Entinostat Offers Patients a Path Back to Normalcy
As treatment options for hormone receptor-positive (HR⁺) breast cancer continue to diversify—from chemotherapy and endocrine therapy to targeted treatments—survival outcomes are improving. However, alongside extended survival, maintaining quality of life (QoL) and enabling patients to return to everyday life have become equally vital goals. Entinostat, a novel histone deacetylase inhibitor (HDACi), stands out with its well-tolerated safety profile and convenient dosing regimen. By enhancing both survival and QoL, it provides new therapeutic possibilities for HR⁺ breast cancer patients. Dr. Jun Cao from Fudan University Shanghai Cancer Center shares insights into managing QoL in the chronic disease era and highlights the clinical advantages of entinostat.